Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camille Tlemsani

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Clinical Therapeutics|July 8, 2020
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older PatientsEvelina Cardoso, Monia Guidi, Nihel Khoudour, et al.
Cold Spring Harbor Molecular Case Studies|October 8, 2020
Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumorsNobuyuki Takahashi, Vinodh N Rajapakse, Lorinc Pongor, et al.
Orthopaedics & Traumatology, Surgery & Research : OTSR|October 30, 2025
Orthopedic Surgical Management of Soft Tissue Sarcomas in a Referral Center: 5-Year Oncological OutcomesDiane Ji Yun Yoon, Pascaline Boudou-Rouquette, Sarah Kreps, et al.
Bulletin Du Cancer|January 23, 2025
Bone sarcomas and cancer predisposition syndromesCamille Tlemsani, Gaëlle Bougeard, Marion Gauthier-Villars, et al.
Iscience|November 3, 2022
Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylationLorinc S Pongor, Camille Tlemsani, Fathi Elloumi, et al.
International Journal of Cancer|August 30, 2018
Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinomaBenoit Rousseau, Aude Guillemin, Christophe Duvoux, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2021
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk managementAudrey Bellesoeur, Ithar Gataa, Anne Jouinot, et al.
Cancers|February 23, 2020
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control StudyManuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 25, 2019
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patientsAnne Jouinot, Guillaume Ulmann, Clara Vazeille, et al.
Journal of Medical Genetics|May 28, 2013
CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre studyPatrick R Benusiglio, David Malka, Etienne Rouleau, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Clinical Therapeutics|July 8, 2020
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older PatientsEvelina Cardoso, Monia Guidi, Nihel Khoudour, et al.
Cold Spring Harbor Molecular Case Studies|October 8, 2020
Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumorsNobuyuki Takahashi, Vinodh N Rajapakse, Lorinc Pongor, et al.
Orthopaedics & Traumatology, Surgery & Research : OTSR|October 30, 2025
Orthopedic Surgical Management of Soft Tissue Sarcomas in a Referral Center: 5-Year Oncological OutcomesDiane Ji Yun Yoon, Pascaline Boudou-Rouquette, Sarah Kreps, et al.
Bulletin Du Cancer|January 23, 2025
Bone sarcomas and cancer predisposition syndromesCamille Tlemsani, Gaëlle Bougeard, Marion Gauthier-Villars, et al.
Iscience|November 3, 2022
Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylationLorinc S Pongor, Camille Tlemsani, Fathi Elloumi, et al.
International Journal of Cancer|August 30, 2018
Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinomaBenoit Rousseau, Aude Guillemin, Christophe Duvoux, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2021
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk managementAudrey Bellesoeur, Ithar Gataa, Anne Jouinot, et al.
Cancers|February 23, 2020
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control StudyManuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 25, 2019
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patientsAnne Jouinot, Guillaume Ulmann, Clara Vazeille, et al.
Journal of Medical Genetics|May 28, 2013
CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre studyPatrick R Benusiglio, David Malka, Etienne Rouleau, et al.
Pageof 6